TCM
ELEV

TCG Crossover Management’s Elevation Oncology ELEV Stock Holding History

TCG Crossover Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-288,390
Closed -$274K – 23
2022
Q4 		$274K Sell
288,390
-266,610
-48% -$271K 0.05% 21
2022
Q3 		$627K Hold
555,000
– – 0.19% 21
2022
Q2 		$777K Hold
555,000
– – 0.33% 21
2022
Q1 		$1.4M Hold
555,000
– – 0.56% 20
2021
Q4 		$3.34M Buy
+555,000
New +$3.83M 1.56% 15

Other funds holding ELEV

ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

TCG Crossover Management's ELEV Position: Q1 2023 in Review

TCG Crossover Management sold out of Elevation Oncology (ELEV) in Q1 2023, closing a stake of 288,390 shares — an estimated $274K sold.

TCG Crossover Management first reported a position in ELEV in Q4 2021 and held it in 5 quarters. The position peaked at $3.34M in Q4 2021. 27 funds tracked by Wall St. Rank hold ELEV as of Q1 2023.

  • TCG Crossover Management reported no remaining Elevation Oncology position as of Q1 2023 after selling out during the quarter.
  • TCG Crossover Management sold 288,390 Elevation Oncology shares in Q1 2023, an estimated $274K.
  • TCG Crossover Management first reported a position in Elevation Oncology in Q4 2021 and held it in 5 quarters.
  • TCG Crossover Management's Elevation Oncology position peaked at $3.34M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2023.

Based on TCG Crossover Management's 13F filing for Q1 2023, filed 15 May 2023.